Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.68 |
| ▸ | ACE | P12821 | 3/20 | 0.68 |
| ▸ | MMEL1 | Q495T6 | 8/20 | 0.67 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572793 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL30889 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL3877643 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1908539 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL597902 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL29046 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL3867666 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL13566634 | 1.00 | MME (0.68) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1232351 | 0.99 | MME (0.67) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231233 | 0.99 | MME (0.67) | MMEACEMMEL1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816871-A | LCZ696 impurity and preparation method thereof | 江苏开放大学（江苏城市职业学院） | 2021-12-21 | — | — | CN | claimed |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-11-02 | — | — | US | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-110845349-B | Purification method of Sacubitril valsartan sodium intermediate | 株洲千金药业股份有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-110845349-A | Purification method of Sacubitril valsartan sodium intermediate | 株洲千金药业股份有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-110818581-A | Post-treatment method of Sacubitril valsartan sodium intermediate | 株洲千金药业股份有限公司 | 2020-02-21 | — | — | CN | claimed |
| US-20200055812-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTALLINE FORM, AMORPHOUS FORM AND PREPARATION METHOD THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-20 | — | — | US | claimed |
| EP-3611160-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| CN-117964521-A | Preparation method of sabatier starter intermediate | 江苏科本药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-108794342-B | Ammonium carboxylate compound, crystal form and amorphous form thereof and preparation method thereof | 武汉朗来科技发展有限公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-3611160-B1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| EP-3611160-B1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| EP-2245009-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009090251-A2 | NEW PROCESSES | NOVARTIS AG (CH) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008031567-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | MME 1/4885ACE 6/4885MMEL1 90/4885 |
| US-11161803-B2 | Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof | ACMSD, ADSL, AMD1 | MME 3513/4885ACE 110/4885MMEL1 4455/4885 |
| US-20200055812-A1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTALLINE FORM, AMORPHOUS FORM AND PREPARATION METHOD THEREOF | ACMSD, ADSL, AMD1 | MME 3513/4885ACE 110/4885MMEL1 4455/4885 |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | MME 16/4885ACE 2/4885MMEL1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.